We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

140 hedge funds and large institutions have $1.84B invested in Dianthus Therapeutics in 2025 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 43 increasing their positions, 34 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

292% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 13

153% more capital invested

Capital invested by funds: $729M → $1.84B (+$1.11B)

83% more funds holding in top 10

Funds holding in top 10: 6 → 11 (+5)

37% more funds holding

Funds holding: 102 → 140 (+38)

26% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 34

23.88% more ownership

Funds ownership: 121.6% → 145.48% (+24%)

9% more call options, than puts

Call options by funds: $15.6M | Put options by funds: $14.3M

Holders
140
Holders Change
+38
Holders Change %
+37.25%
% of All Funds
1.84%
Holding in Top 10
11
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+83.33%
% of All Funds
0.14%
New
51
Increased
43
Reduced
34
Closed
13
Calls
$15.6M
Puts
$14.3M
Net Calls
+$1.32M
Net Calls Change
-$790K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$64M
2
APM
Avidity Partners Management
Texas
+$37.3M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$36.5M
4
B
Braidwell
Connecticut
+$21.3M
5
PCH
Polar Capital Holdings
United Kingdom
+$19.1M

Top Sellers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
-$51.6M
2
DTC
Deep Track Capital
Connecticut
-$41.6M
3
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
-$29.8M
4
5VM
5AM Venture Management
California
-$15.8M
5
WP
Woodline Partners
California
-$9.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
Balyasny Asset Management
26
Balyasny Asset Management
Illinois
$17.5M +$11.3M +443,703 New
NCM
27
Nantahala Capital Management
Connecticut
$14.8M +$9.58M +375,000 New
5VM
28
5AM Venture Management
California
$14.4M -$15.8M -619,672 -63%
VC
29
Vivo Capital
California
$13.9M +$9.05M +353,998 New
IC
30
Ikarian Capital
Texas
$13.6M +$8.84M +346,001 New
CS
31
Candriam SCA
Luxembourg
$11.9M +$1.56M +60,852 +25%
GPP
32
Great Point Partners
Connecticut
$10.5M +$6.79M +265,803 New
TCM
33
Tang Capital Management
California
$10.4M – – –
AAA
34
Affinity Asset Advisors
New York
$10.3M +$6.7M +262,100 New
Goldman Sachs
35
Goldman Sachs
New York
$8.61M -$3.73M -145,821 -40%
T. Rowe Price Associates
36
T. Rowe Price Associates
Maryland
$8.51M +$5.25M +205,443 +1,921%
AI
37
Alphabet Inc
California
$8.21M – – –
Barclays
38
Barclays
United Kingdom
$8.04M +$3.57M +139,548 +215%
LGM
39
Logos Global Management
California
$7.87M +$5.11M +200,000 New
Charles Schwab
40
Charles Schwab
California
$7.6M +$735K +28,746 +17%
TLP
41
Tri Locum Partners
New York
$7.2M +$4.67M +182,867 New
Bank of America
42
Bank of America
North Carolina
$7.08M +$381K +14,900 +9%
RPAM
43
Rhenman & Partners Asset Management
Sweden
$6.83M +$1.2M +47,000 +37%
Northern Trust
44
Northern Trust
Illinois
$6.2M -$71.1K -2,784 -2%
IHAM
45
Integral Health Asset Management
New York
$5.9M +$3.83M +150,000 New
Millennium Management
46
Millennium Management
New York
$5.75M -$1.26M -49,191 -25%
Walleye Capital
47
Walleye Capital
New York
$5.55M +$2.94M +114,996 +440%
BFM
48
Boothbay Fund Management
New York
$5.47M +$3.55M +138,963 New
CM
49
Caption Management
Oklahoma
$5.45M +$3.54M +138,561 New
UBS Group
50
UBS Group
Switzerland
$5.39M +$143K +5,592 +4%
1
2
3 4 5

DNTH Hedge Fund Activity: Q3 2025 in Review

140 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2025, worth a combined $1.84B — up 153% from $729M a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new DNTH positions and 13 closed out — a net gain of 38 holders — while 43 added to existing stakes and 34 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $64M. The largest seller was Vestal Point Capital, cutting an estimated $51.6M.

  • 140 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2025, up from 102 in Q2 2025.
  • Funds reported $1.84B of Dianthus Therapeutics stock for Q3 2025, up 153% quarter-over-quarter.
  • 51 funds opened new Dianthus Therapeutics positions in Q3 2025 and 13 closed out, a net change of +38 holders.
  • The largest Dianthus Therapeutics buyer in Q3 2025 was Wellington Management Group, an estimated $64M added.
  • The largest Dianthus Therapeutics seller in Q3 2025 was Vestal Point Capital, an estimated $51.6M sold.

Based on aggregated 13F filings for Q3 2025.